Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08GFN
|
|||
| Former ID |
DNCL003168
|
|||
| Drug Name |
MVA-BN Breast
|
|||
| Synonyms |
MVA-BN-pRo (TN)
Click to Show/Hide
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 1 | [1] | |
| Company |
BN ImmunoTherapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostate specific antigen (KLK3) | Target Info | Antagonist | [2], [3] |
| KEGG Pathway | Pathways in cancer | |||
| Prostate cancer | ||||
| Pathway Interaction Database | Coregulation of Androgen receptor activity | |||
| Regulation of Androgen receptor activity | ||||
| FOXA1 transcription factor network | ||||
| Reactome | Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | |||
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | ||||
| WikiPathways | Prostate Cancer | |||
| Androgen receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00629057) A Safety Trial of MVA-BN-PRO in Men With Androgen-Insensitive Prostate Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res. 2011 Aug 1;71(15):5235-44. | |||
| REF 3 | J Clin Oncol 31, 2013 (suppl 6; abstr 193). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.